Industry Symposia

 Friday, April 29
Lunch Symposium - 12:15-13:30
Treatment strategies to improve outcomes in RRMM

 Supported by
12:15-12:20
Welcome and meeting objectives
Prof. Philippe Moreau
 
12:20-12:35
Predicting high-rsik RRMM: To highlight genetic instability and clonal evolution that underlie high-risk RRMM
Prof. Herve Avet-Loiseau
 
12:35-12:55
Improving outcomes in RRMM: Synergies with proteasome inhibitors and IMiDS: To summarise preclinical and clinical evidence supporting PI and IMiD combination therapy
Prof. Pieter Sonneveld
 
12:55-13:15
Building on the oral proteasome inhibitor story in RRMM: Understanding the new treatment landscape
Prof. Maria Victoria Mateos
 
13:15-13:30
Conclusions and Q&A
Prof. Philippe Moreau
 
 
 
Saturday, April 30
Lunch Symposium - 13:15-14:30
Understanding the role of epigenetics in the pathogenesis and treatment of
multiple myeloma
 Supported by

13:15-13:30
Welcome and Opening remarks
Prof. Thierry Facon (Lille)
  
13:30-13:55
Rationale for targeting epigenetic mechanisms in multiple myeloma
Prof. Paul Richardson (USA)
  
13:55-14:20
Clinical update on pan-deacetylase inhibitors in multiple myeloma
Prof. Paul Richardson (USA)
 
14:20-14:30
Q&A
Prof. Thierry Facon (Lille)